Financings in Brief: Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive Summary
Advanced Tissue Sciences: Files registration statement with the Securities and Exchange Commission for an offering of 3 mil. shares of common stock, the tissue engineering firm announces Feb. 23. Proceeds from the offering will fund "the scale up of manufacturing, sales and marketing, clinical trials and continued research and development," the firm says. Stock in the La Jolla, California company -- in clinical trials with DermaGraft products for treatment of severe burns and diabetic foot ulcers -- closed Feb. 22. at $10.25 per share. Goldman, Sachs and Morgan Stanley are underwriting and hold an option to buy 450,000 over-allotment shares...